Dopaminergic Regulation of the Serotonergic Raphe-Striatal Pathway: Microdialysis Studies in Freely Moving Rats

Sergi Ferré, Roser Cortés, and Francesc Artigas
Department of Neurochemistry, Centro de Investigación y Desarrollo, C.S.I.C., 08034 Barcelona, Spain

Morphological evidence demonstrates the existence of dopaminergic afferent pathways and dopamine (DA)-containing neurons in the dorsal raphe nucleus (DRN). In a recent report, a DA D₂-like receptor-mediated regulation of serotonin (5-HT) extracellular concentration in DRN has been found. Given the existence of somatodendritic 5-HT₁₅ autoreceptors in the DRN, changes of the extracellular concentration of 5-HT in the vicinity of cell bodies and dendrites may be relevant for the control of the activity of ascending serotonergic pathways. In the present brain microdialysis study we have used a chromatographic method (HPLC) enabling the simultaneous measurement of DA, 5-HT, and their main metabolites dihydroxyphenylacetic acid (DOPAC) and 5-hydroxyindoleacetic acid (5-HIAA). The presence of a neuronal pool of DA within the DRN was revealed by the local infusion of amphetamine (10 μM), which significantly increased the extracellular concentration of both amines. The local striatal infusion (10 μM) of the selective DA D₁-like agonist SKF-38393, the selective DA D₂-like agonist quinpirole (LY 171,555), or the nonselective DA agonist apomorphine markedly decreased DA and DOPAC extracellular concentrations and failed to modify 5-HT or 5-HIAA in the striatum, indicating the lack of terminal (striatal) control of 5-HT release by dopaminergic transmission. In contrast, the systemic administration of apomorphine (2.8 μmol/kg, s.c.) significantly increased the extracellular concentration of 5-HT in the DRN and decreased it in the striatum. The reduction of striatal 5-HT extracellular concentration was prevented by the previous administration of the selective 5-HT₁₅ receptor antagonist WAY 100135 (17.6 μmol/kg, s.c.), which by itself did not change extracellular 5-HT in striatum. These results support that dopaminergic neurotransmission inhibits the activity of DRN-striatal neurons by increasing 5-HT extracellular concentration in DRN and, consequently, by increasing somatodendritic 5-HT₁₅ autoreceptor stimulation in this nucleus.

[Key words: dorsal raphe nucleus, striatum, serotonin, dopamine, dopamine D₁-like receptors, dopamine D₂-like receptors, serotonin 5-HT₁₅ receptors, in vivo microdialysis]

Received Sept. 30, 1993; revised Jan. 25, 1994; accepted Feb. 8, 1994.

This work was supported by grants from the tondo de Investigacio sanitaria (FIS 92/0268) and the EEC (STEP contract CT91-003). We gratefully acknowledge the technical assistance of Josefa Torres and Leizia Campa. We thank Wyeth Research UK (Maidenhead, UK) for the supply of WAY 100135. Clozapine was a generous gift of Lundbeck (Copenhagen, DK).

Correspondence should be addressed to Dr. Francesc Artigas, Department of Neurochemistry, C.S.I.C., Jordi Girona 18-26, E-08034 Barcelona.

Copyright © 1994 Society for Neuroscience 0270-6474/94/144839-08$05.00/0

The Journal of Neuroscience, August 1994, 14(8): 4839–4846
for review). Using the microdialysis technique, we recently found a DA D,-like receptor-mediated regulation of 5-HT extracellular concentration in the DRN of unanesthetized rats. Local infusion of the nonselective DA receptor agonist apomorphine or the selective DA D,-like receptor agonist quinpirole induced an increase of extracellular 5-HT in the DRN that was antagonized by the DA D,-like receptor antagonist raclopride, but not by the DA D,-like antagonist SCH 23390 (Ferrié and Artigas, 1993). The existence of somatodendritic 5-HT,, autoreceptors that inhibit electrical activity (Sprouse and Aghajanian, 1987, 1988), 5-HT synthesis (Hjorth and Magnusson, 1988; Hutson et al., 1989; Invernizzi et al., 1991), and 5-HT release in projection areas (Hutson et al., 1989; Sharp et al., 1989a; Bonvento et al., 1992; Adell et al., 1993) is well documented (Pazos and Palacios, 1985; Vergé et al., 1986; Sotelo et al., 1990). Therefore, an increased dopaminergic transmission within the DRN may inhibit the activity of ascending DRN serotonergic neurons through an enhancement of 5-HT extracellular concentration in DRN and further activation of 5-HT,, autoreceptors. Indeed, pharmacologically induced increases of extracellular 5-HT in the raphe nuclei reduce terminal 5-HT synthesis and/or release, as measured with the push–pull cannula in the cat (Becquet et al., 1990) or in vivo microdialysis in awake, freely moving rats (Adell and Artigas, 1991).

In the present study, we have examined the effects of dopaminergic agents on extracellular 5-HT in the DRN and DA and 5-HT in the striatum. The data obtained support the view that
an increased dopaminergic activity results in opposite changes of extracellular 5-HT in DRN and striatum.

Materials and Methods

Animals. Male Wistar rats weighing 290–310 gm were used. They were housed four per cage and kept in a controlled environment (12 hr light/dark cycle and 22 ± 2°C room temperature). Food and water were provided ad libitum. Animal care followed the Spanish legislation on “Protection of Animals Used in Experimental and Other Scientific Purposes,” in agreement with the European (E.E.C.) regulations (O.J. of E.C. L135/1/18/12/1986).

Surgery. Concentric dialysis probes were made as previously described (Adell and Artigas, 1991), with the exception that the length of the micropipette tip was doubled, and the brain tissue was either 1.5 mm or 4.0 mm long (0.25 mm o.d.). Before implantation, rats were anesthetized with sodium pentobarbital (60 mg/kg, i.p.) and placed in a stereotaxic frame. Dialysis probes (1.5 mm) were implanted in the DRN with a lateral angle of 30° and the following coordinates, in millimeters, with respect to bregma: AP = -7.8, L = 3.1, D = -7.5 (Paxinos and Watson, 1982). Dialysis (4 mm) probes were implanted in the striatum with the following coordinates, in millimeters, with respect to bregma: AP 0.2, L 3.0, D -8.0 (Paxinos and Watson, 1982). The location of the dialysis probes is shown in Figure 1.

Microdialysis procedure. Animals were allowed to recover from surgery for approximately 18–20 hr and then probes were perfused with artificial cerebrospinal fluid (125 mM NaCl, 2.5 mM KCl, 1.26 mM CaCl₂, and 1.18 mM MgCl₂; pH 6.2) at 0.5 μl/min using a CMA/100 microdialysis pump (Carnegie Medicin, Stockholm, Sweden). Sample collection started 60 min after the beginning of perfusion. Usually four or five basal fractions were collected to obtain basal values before either local infusion of systemic administration of drugs. Local administration was performed by reverse dialysis, dissolving the appropriate amounts of each drug in the perfusion fluid. Systemic administrations were carried out intraperitoneally using 5% glucose as vehicle (injection volume of 2 ml/kg). The effects of systemic apomorphine on extracellular 5-HT in DRN and striatum were performed in separate groups of rats. Given the small size of the 1.5 mm dialysis probes, citoblastin (1 μm) was added to the artificial CSF to increase the detectability of serotonin when probes were implanted within the DRN. Successive 30 min (15 μl) dialysate samples were collected. At the end of the experiment, the probe placement was verified by injection of methylene blue and visual inspection. Animals with a placement of the probe outside the DRN [indicated also by a low extracellular 5-hydroxyindoleacetic acid (5-HIAA) concentration; see Discussion] were discarded. The in vitro percentage recoveries of the 1.5 mm dialysis probes for DA, dihydroxyphenylacetic acid (DOPAC), 5-HT, and 5-HIAA were, respectively, (flow rate = 0.5 μl/min): 20.1 ± 0.9, 21.9 ± 0.6, 23.8 ± 1.8, and 18.3 ± 0.8 (n = 4, mean ± SEM). For the 4.0 mm dialysis probes these figures were, respectively, 50.6 ± 1.4, 42.2 ± 1.2, 44.7 ± 0.9, and 38.7 ± 0.5 (n = 4, mean ± SEM).

Drugs and reagents. Apomorphine, 5-HT, 5-HIAA, DA, and DOPAC were from Sigma (St. Louis, MO). Quinpirole ([+-]LY 171,555) and (+)SKF-38393 were from RBI (Natick, MA). d-Amphetamine was from the Service of Psychotropic Substances, Ministry of Health, Madrid, Spain. Other materials and reagents were from local commercial sources.

Chromatographic analysis. DA, DOPAC, 5-HT, and 5-HIAA were analyzed by a modification of the HPLC method described in Adell and Artigas (1991). The composition of HPLC eluent was as follows: 0.1 M NaH₂PO₄, 0.46 mM octyl sodium sulfate, 0.5 mM EDTA (pH 2.8 adjusted with phosphoric acid), and 18% methanol. The catechol and indole compounds were separated on a 3 μm ODS 2 column (7.5 cm × 0.46 cm; Beckman, CA) and detected amperometrically with a Hewlett Packard 1049 detector, with a limit of detection of 0.5–1 fmol for standard DA and 5-HT (Fig. 2). This HPLC method enabled the simultaneous detection of DA, 5-HT, and their acidic metabolites in the same dialysate samples.

Data analysis. In each experiment the results (expressed as means ± SEM) are given as percentage of basal values. The statistical analysis used was the “summary measures” method (Mathews et al., 1990), using the mean of the four values previous to drug administration and the mean of the five values subsequent to drug administration per animal as the summary measures. Post- versus predrug values were compared using Student’s paired t test to analyze drug effects. p values refer in all cases to these differences.
Discussion

Owing to the development of a new HPLC procedure, we have been able to determine low (0.5–1 fmol) amounts of 5-HT and DA in the same dialysate samples from the DRN and striatum. This enabled the simultaneous study of both amines in the same animal. The HPLC method devised is particularly useful for the analysis of DA and 5-HT at very low concentrations, given their short retention times and the consequent increase in detectability. The present results demonstrate for the first time the occurrence of a measurable extracellular concentration of DA in the DRN. The somatodendritic or terminal origin of this DA is unclear, since both dopaminergic terminals from the SN or VTA (Afifi and Kaelber, 1965; Pasquier et al., 1977; Sakai et al., 1977; Lee and Geyer, 1984; Kalivas et al., 1988) and DA-containing neurons within the DRN (Hökfelt et al., 1987; Gefard et al., 1987; Kalén et al., 1988) have been described. The present results cannot clarify this issue, since amphetamine releases both terminal and somatodendritic DA (Kalivas and Duff, 1991; Robertson et al., 1991). In any case, the increased extracellular DA after the local administration of amphetamine indicates the existence of a releasable pool of DA close to se-

---

**Figure 4.** Effect of intrastriatal infusion of the nonselective DA agonist apomorphine (10 μmol/liter) on extracellular concentrations of DA, DOPAC, 5-HT, and 5-HIAA in the striatum. Data are mean ± SEM values (n = 4) and are given as percentages of baseline values, determined from the mean of the two values previous to drug infusion. The horizontal line indicates the period of drug infusion.

**Figure 5.** Effect of intrastriatal infusion of the selective DA D₂-like agonist SKF-38393 (10 μmol/liter) on extracellular concentrations of DA, DOPAC, 5-HT, and 5-HIAA in the striatum. Data are mean ± SEM values (n = 4) and are given as percentages of baseline values, determined from the mean of the two values previous to drug infusion. The horizontal line indicates the period of drug infusion.

**Figure 6.** Effect of intrastriatal infusion of the selective DA D₁ agonist LY-171555 (quipinrole) (10 μmol/liter) on extracellular concentrations of DA, DOPAC, 5-HT, and 5-HIAA in the striatum. Data are mean ± SEM values (n = 4) and are given as percentages of baseline values, determined from the mean of the two values previous to drug infusion. The horizontal line indicates the period of drug infusion.

**Figure 7.** Effect of systemic administration of the nonselective DA agonist apomorphine (apo) (2.8 μmol/kg) on extracellular concentration of 5-HT in the DRN and in the striatum. Data are mean ± SEM values (n = 5 in both cases) and are given as percentages of baseline values, determined from the mean of the two values previous to drug infusion. The arrow indicates the time of apomorphine injection.
The selective DA D₃-like receptor agonist quinpirole induced a decrease of extracellular concentration. Thus, the local infusion of 10 μmol/liter of the nonselective DA receptor agonist apomorphine (apo) (2.8 μmol/kg, s.c.) on the extracellular concentration of 5-HT in the striatum. Data are mean ± SEM values (n = 4 in both cases) and are given as percentages of baseline values, determined from the mean of the two values previous to apomorphine administration. The arrows indicate the times of drug administration.

rhotonergic cell bodies and dendrites in the DRN, a nucleus that contains a substantial density of DA D₃-like receptors (Bouthenet et al., 1987; Palacios and Pazos, 1987). This suggests that the DA–5-HT interaction found within the DRN in this and a previous study (Ferré and Artigas, 1993) may be physiologically relevant for the control of ascending serotonergic pathways. 5-HT extracellular concentration was also increased by the local administration of amphetamine in the DRN. This is in accordance with data in the literature indicating an in vivo releasing action of amphetamine on 5-HT, as measured by microdialysis (Parada et al., 1988), although an indirect action caused by the increased DA may also contribute.

The basal concentration of extracellular 5-HT was not dependent on a precise position of the probe in the DRN, as observed in rats with an incorrect placement (not included in the study). In contrast, a high extracellular 5-HIAA concentration was a good indicator of the location of the probe within the boundaries of the DRN. This agrees with data showing that the basal extracellular concentration of 5-HT, as measured with microdialysis, is independent to a large extent on the density of innervation, thus reflecting the equilibrium between release and reuptake (Adell et al., 1991; Jackson and Abercrombie, 1992). However, since 5-HIAA lacks any reuptake system, its extracellular concentration is determined by its tissue content, higher in the raphe nuclei than in other brain areas (Adell et al., 1991).

The results obtained in this study extend previous observations indicating that (1) dopaminergic transmission increases extracellular 5-HT in the DRN, presumably through D₃-like receptors (Ferré and Artigas, 1993), and (2) the increased availability of 5-HT at somatodendritic 5-HTₐ autoreceptors results in decreases of terminal serotonergic release (Becquet et al., 1990; Adell and Artigas, 1991).

In agreement with data in the literature, the striatal application of dopaminergic agonists induced a marked decrease of DA extracellular concentration. Thus, the local infusion of 10 μmol/liter of the nonselective DA receptor agonist apomorphine, the selective DA D₃-like receptor agonist apomorphine, the selective DA D₃-like receptor agonist SKF 38393, or the selective DA D₃-like receptor agonist quinpirole induced a strong and sustained decrease of striatal DA extracellular concentration. Similarly, DOPAC extracellular concentrations were significantly decreased by the local infusion of DA agonists. These reductions are most probably due to the activation of D₃-like release-inhibiting autoreceptors (by apomorphine and quinpirole) or postsynaptic D₃-like receptors (by apomorphine and SKF 38393) located in striatonigral GABA neurons that control the activity of nigrostrial dopaminergic neurons (Imperato and Di Chiara, 1988; Reid et al., 1990; Fuxe et al., 1992).

In contrast, striatal 5-HT and 5-HIAA extracellular concentrations in the same animals were unchanged after a dose (10 μmol/liter) of apomorphine and quinpirole that increased 5-HT concentration in DRN (Ferré and Artigas, 1993). Hence, whereas 5-HT promotes DA striatal release when applied locally (Blandina et al., 1989; Benlouieif and Galloway, 1991), the activation of dopaminergic D₃-like and D₃-like receptors in the striatum does not result in local changes of 5-HT release. Clearly, this indicates an interaction of serotonergic transmission on terminal (striatal) dopaminergic function but not the opposite. Yet the local and systemic administration (this study) of the DA agonist apomorphine increased raphe extracellular 5-HT, an effect mediated by D₃-like receptors in the DRN (Ferré and Artigas, 1993). An increased intra- and extracellular concentration of 5-HT in DRN, as measured by a histofluorescence method, has already been reported after the systemic treatment with apomorphine (Lee and Geyer, 1984). However, these authors described a 1:3 ratio for extra-versus intracellular 5-HT, whereas it is widely accepted that this ratio is over 1:1000 for most neurotransmitters (Westerink et al., 1987) in different brain areas, including 5-HT in the raphe nuclei (Adell et al., 1991). Therefore, the relationship of the present in vivo results with the increased extracellular histofluorescence found by these authors is unclear. Also, apomorphine was reported to increase slightly (+12%) the striatal (but not the hippocampal) total tissue content of 5-HT (Lee, 1987), whereas a reduction of striatal extracellular 5-HT has been found here. This discrepancy is likely to be due to the measurement of active (extracellular) and reserve (intracellular) pools when total tissue concentrations are involved. In contrast, only active pools of the transmitter are measured with the microdialysis technique.

The opposite changes of extracellular 5-HT in DRN (increase) and striatum (decrease) induced by the systemic administration of apomorphine suggest that DA may inhibit the activity of ascending serotonergic pathways originating in the DRN via an action of the extracellular concentration of 5-HT in DRN. Presumably, the reduction of striatal extracellular 5-HT results from the activation of somatodendritic 5-HTₐ receptors located in DRN (Pazos and Palacios, 1985; Vergé et al., 1986; Sotelo et al., 1990) secondary to the increase of 5-HT induced by apomorphine. Extracellular concentration of 5-HT in the midbrain raphe region is in the low nanomole/liter range (Adell et al., 1993), close to its affinity for 5-HTₐ receptors (Pedgo et al., 1981). Hence, increases of 5-HT availability in the vicinity of serotonergic cell bodies and dendrites may result in decreased terminal synthesis and/or release, as shown previously (Becquet et al., 1990; Adell and Artigas, 1991). Interestingly, the reduction of striatal extracellular 5-HT appears to be delayed with respect to the increase produced in DRN. This seems to be at variance with the fact that terminal 5-HT release increases shortly after the electric stimulation of the DRN (Sharp et al., 1989b, 1990), indicating a firing-coupled release. However, the maximal reductions of terminal 5-HT output in frontal cortex or
striatum, two areas receiving a prominent DRN innervation, after the local (intraraphe) application of direct (8-OH-DPAT; Bonvento et al., 1992) and indirect (clomipramine; Adell and Artigas, 1991) 5-HT1 antagonists are delayed with respect to the drug application. This delay has also been observed by Becquet et al. (1990). These authors found a decreased [3H]-5-HT release (newly synthesized from superfused [3H]-tryptophan) in the caudate of cats during the perfusion of a 5-HT-releasing agent in the DRN. The reduced [3H]-5-HT release in striatum persisted at least for 1 hr after the withdrawal of the 5-HT-releasing agent in DRN, a time when 5-HT release in DRN had almost regained normal levels. This is indicative that the diminished 5-HT terminal release may not be an immediate consequence of the suppression of firing at the somatodendritic level by 5-HT or 5-HT1a agonists (Blier et al., 1987; Sprouse and Aghajanian, 1987; Sinton and Fallon, 1988) and points toward a reduction of a terminal 5-HT releasable pool as a likely cause of the decreased 5-HT extracellular concentration in terminal areas. Indeed, 5-HT1a agonists markedly reduce terminal 5-HT synthesis when applied locally in the DRN (Hutson et al., 1989; Invernizzi et al., 1991), the striatum and prefrontal cortex being the two most sensitive brain areas (Invernizzi et al., 1991).

That the reduction of extracellular 5-HT in the striatum following systemic administration of apomorphine may be secondary to the increase of 5-HT in the DRN is also supported by the lack of a local action of the dopaminergic agonists (see Figs. 4-6) and the blockade of the effect with the systemic treatment with WAY 100135, a selective antagonist of pre- (somatodendritic) and postsynaptic 5-HT1a receptors (Fletcher et al., 1993; Routledge et al., 1993). At the dose used (17.6 μmol/kg), this compound prevents the reduction of hippocampal 5-HT release induced by the occupation of somatodendritic 5-HT1a receptors by the selective agonist 8-OH-DPAT (Routledge et al., 1993; Romero et al., unpublished observations). The injection of WAY 100135 alone did not modify the basal 5-HT output in striatum. This agrees with previous reports indicating that 5-HT1a autoreceptors in the DRN are not tonicallv activated (Innis and Aghajanian, 1987; Trulson and Frederickeon, 1987; Becquet et al., 1990).

Interestingly, Stern et al. (1981) found an almost complete suppression of unit activity in DRN following electrical stimulation of the substantia nigra that, unlike that obtained by stimulation of the lateral habenula, could not be blocked by picrotoxin. This indicates the existence of a functional inhibitory nigro-raphe pathway not involving GABAergic interneurons in the DRN. The results obtained in the present and previous (Ferre and Artigas, 1993) studies support the view that the excess 5-HT in the interstitial space in the DRN after dopaminergic D1-like activation may participate in the suppression of unit activity found previously (Stern et al., 1981), through the hyperpolarization of serotonergic cells mediated by the opening of 5-HT1a-gated K+ channels (Innis and Aghajanian, 1987; Haj-Dahmene et al., 1991).

In summary, the present results provide neurochemical support for an inhibitory dopaminergic control of ascending serotonergic pathways, mediated at the somatodendritic level (in DRN) through increases of the extrasynaptic 5-HT concentration. The lack of a local action of dopaminergic agents precludes a DA-mediated control of striatal 5-HT release at the terminal level. The origin of the dopaminergic afferents responsible for these effects is uncertain and must await further studies.

References
Guan X-M, McBride W (1989) Serotonin microinfusion into the ven-


